Kidney Disease

Nephrology
7
Pipeline Programs
5
Companies
4
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
2
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 7 programs with unclassified modality

On Market (1)

Approved therapies currently available

Amgen
ARANESPApproved
darbepoetin alfa
Amgen
Erythropoiesis-stimulating Agent [EPC]subcutaneous2001

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
4 programs
2
2
Aranesp®Phase 41 trial
SensiparPhase 41 trial
Darbepoetin AlfaPhase 31 trial
darbepoetin alfa SFPhase 31 trial
Active Trials
NCT00111098Completed150Est. Nov 2005
NCT00093977Completed1,100Est. Jan 2007
NCT00117130Completed
+1 more trials
BioMarin Pharmaceutical
1 program
1
6R BH4Phase 21 trial
Active Trials
NCT00625820Completed17Est. Sep 2008
Palatin Technologies
1 program
1
BremelanotidePhase 2Peptide1 trial
Active Trials
NCT05709444CompletedEst. Apr 2024
Astellas
AstellasChina - Shenyang
1 program
DBS for Home Monitoring in Children With Kidney TransplantationN/A1 trial
Active Trials
NCT01931397Completed30Est. Feb 2015
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
xevontaN/A1 trial
Active Trials
NCT01111266Completed12Est. Mar 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AmgenSensipar
Amgendarbepoetin alfa SF
AmgenDarbepoetin Alfa

Clinical Trials (4)

Total enrollment: 1,550 patients across 4 trials

NCT00117130AmgenAranesp®

Study to Evaluate Effectiveness of Aranesp®

Phase 4Completed
NCT00132431AmgenSensipar

START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism

Start: Jul 2004Est. completion: Jul 2005300 patients
Phase 4Completed
NCT00093977Amgendarbepoetin alfa SF

Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease

Start: Oct 2004Est. completion: Jan 20071,100 patients
Phase 3Completed
NCT00111098AmgenDarbepoetin Alfa

Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis

Start: Mar 2004Est. completion: Nov 2005150 patients
Phase 3Completed

Related Jobs in Nephrology

Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery

AstraZeneca
Sweden - Gothenburg
6d ago

Director, Strategy & Operations-Nephrology Franchise

Biogen
Cambridge, MA
1w ago
$195K - $269K/yr

Associate Director – Nephrology Market Access Strategy

Biogen
Cambridge, MA
1w ago
$164K - $226K/yr

Vice President, Head of Renal Sales

Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr

Medical Science Liaison, CardioRenal - Portland, OR

AstraZeneca
Portland - OR, US
1w ago

Area Sales Manager (Florida Region)

Outset Medical
Florida Region
1w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space

Related Indications

Chronic Kidney Disease(86)Renal Impairment(67)End Stage Renal Disease(56)Kidney Transplantation(49)Renal Insufficiency(27)Chronic Kidney Diseases(25)Kidney Transplant(19)Diabetic Nephropathies(18)Kidney Diseases(17)Kidney Transplant Rejection(16)